-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Thinking, communicating, summarizing, and seeking development are the driving forces for the development of medicine, and they are also the habits
that doctors in the field of blood have adhered to for decades.
Although there was a pre-epidemic, it could not resist the pace
of their exchanges and discussions.
On November 10, 2022, the "25th National Congress of Clinical Oncology, 2022 CSCO Academic Annual Conference, 10th CSCO Leukemia and Lymphoma Expert Committee Academic Conference, 7th Anti-leukemia and Lymphoma International Summit Forum and CSCO Leukemia Leukemia and Leukemia" hosted by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee and CSCO Lymphoma Expert Committee, and hosted by Harbin Institute of Hematological Oncology and Peking University Cancer Hospital were held by Harbin Institute of Hematological Oncology and Peking University Cancer Hospital & Lymphoma Expert Committee Tour - Harbin Station" officially kicked off
.
On the morning of the 10th, the leukemia and lymphoma special session 1 was launched in the form of a combination of online and offline, Professor Ma Jun of Harbin Institute of Hematology and Oncology, Professor Zhu Jun of Peking University Cancer Hospital, Professor Huang Huiqiang of Sun Yat-sen University Cancer Center and
Professor Su Liping of Shanxi Cancer Hospital served as the chairman of the conference.
, Professor Ma Jun served as the host of the opening ceremony, extended a warm welcome to all participants, and said that the epidemic situation is severe but cannot stop the heart of learning and communication, thank you very much for coming to this meeting, and thank you for your attention and participation
。 This conference has invited a number of well-known scholars at home and abroad, looking forward to your wonderful sharing! Subsequently, Professor Zhu Jun said that he hoped that we could meet offline as soon as possible, and was pleased that this conference provided an opportunity for scholars in the field of lymphoma to learn from each other, and believed that with the joint attention and support of experts and scholars in the field of hematology and front-line clinicians across the country, this conference could be a complete success
.
Professor Ma Jun delivered a speech
Professor Zhu Jun delivered a speech
The first half of the academic session was chaired by Professor Ma Jun and Professor Zhu Jun
.
Professor Ma Jun and Professor Zhu Jun served as chairs
Integrate and analyze the big data of Chinese lymphoma
Professor Liu Weiping of Peking University Cancer Hospital gave a detailed report
on the topic of "Big Data Analysis of Lymphoma in China".
Professor Liu Weiping mentioned that through the attribution analysis of the changes in lymphoma mortality, it was found that the burden of lymphoma disease in China has decreased
significantly with the emergence of standardized treatment, the emergence of new drugs and new methods and the increase in the accessibility of medical resources.
In 2021, the utilization rate of ASCT in China is still low, and there are 2443 cases of ASCT for the first time in lymphoma, with a utilization rate of 2.
4%.
Subsequently, Professor Liu Weiping introduced the construction of the lymphoma standard database and the preliminary analysis results of 10,000 representative data, and pointed out that lymphoma big data analysis can accurately guide the standardized diagnosis and treatment of various regions, strongly support the revision and formulation of industry guidelines and specifications, and provide data support for the formulation of lymphoma prevention and treatment policies, so as to carry out real-world research, explore new targets, and promote new drug research and development
.
Professor Liu Weiping gave a wonderful speech
Talk about the turning point of PTCL treatment
American Cancer Society Owen A.
O'Connor is the author of Are We Finally Turning the Corner in PTCL? How Biology and New Drugs are Changing our Direction" gave a wonderful explanation
.
Professor Owen said that since the emergence of CHOP (cyclophosphamide + doxorubicin + vincristine + prednisone) regimen in 1993, peripheral T-cell lymphoma (PTCL) treatment has entered a state of stagnation for nearly 30 years, and some studies have shown that the marketing of bbutuximab (BV) and romidecin (Ro) has not brought a breakthrough
.
Although the current new drugs still have their limitations, there is no lack of opportunities in terms of drugs, and new drugs with active PTCL may be explored as new therapeutic directions, and the addition of new drugs to treatment may bring greater survival benefits
to patients than traditional chemotherapy.
Single- and combination therapies for new drugs such as demethylating drugs, HDAC inhibitors, EZH2 inhibitors, and PI3K inhibitors are all subject to continued research, and innovative preclinical basic research will also increase our chances of
success.
"
Professor Owen A.
O'Connor gave a wonderful speech
For a long time, we praise the research and development under the new crown epidemic
Professor Song Yuqin of Peking University Cancer Hospital gave a wonderful report
on "The Impact of the New Crown Epidemic on the R&D of New Drugs for Lymphoma in China".
As of 2021, 30 new projects have been initiated and 110 projects are under research; From 2016 to 2022, the projects of the Northern Lymphoma Department that have been verified by the Center for Drug Evaluation/the US Food and Drug Administration (CDE/FDA) are still in a steady and gradual upward state
.
In the past ten years, Beiyang has entered the era of targeted therapy and immunotherapy, opening the era of original drugs going overseas and the era of cell therapy, with clinical projects increasing by 20 times and the number of new drugs on the market increasing by 30 times
.
During the epidemic, the "remote monitoring system" was urgently trialed, and the intelligent quality control of clinical research, intelligent subject recruitment, and the first special project
in the direction of research-oriented wards were achieved.
Under the epidemic situation, under the condition of ensuring that previous research is not affected, the attention to new drug research and development has not decreased, and the pace of platform construction and information construction has never stopped
.
Professor Song Yuqin gave a wonderful report
The second half of the academic session was moderated by Professor Huang Huiqiang and Professor Su Liping
.
Professor Wong Wai Keung and Professor Su Liping moderated
Keep up with the frontier and take stock of the new progress in PTCL treatment
Professor Bai Ou of the First Hospital of Bethune of Jilin University elaborated on the classification of PTCL, incidence, regional characteristics, prognosis, and first-line treatment options with the title of "Progress in First-line Treatment of Peripheral T-cell Lymphoma
".
Professor Bai Ou pointed out that with the emergence of new drugs, although the prognosis of mature T/NK cell lymphoma has improved, it is still poor, and more effective clinical evaluation and treatment are
still needed.
Autologous hematopoietic stem cell transplantation (ASCT) for consolidation therapy brings clinical benefits to patients with treatment-naïve PTCL, which deserves attention
.
Patients with PTCL should be treated with stratified therapy, and BV is recommended for patients with CD30-positive PTCL; Younger patients can use the CHOPE (CHOP + ethylposide foot) regimen; ASCT may be considered in high-risk patients; Patients with follicular helper T cells (TFH)/angioimmunoblastic T cell lymphoma (AITL) can be treated with cidarbenamide; Older patients with serious complications may choose a targeted combination chemotherapy-free regimen
.
Professor Bai Gull gave a wonderful speech
Vientiane update, dig deep into the new progress of DLBCL related research
Professor Franco Cavalli of the Bellinzona Research Centre (CH) of the Southern Institute of Oncology (IOSI) of Switzerland gave a detailed introduction
on the topic of "What's New in Aggressive Lymphomas, mainly DLBCL", from the disease characteristics of diffuse large B-cell lymphoma (DLBCL) to the latest treatment progress of DLBCL 。 DLBCL, the most common type of non-Hodgkin lymphoma (NHL), accounts for about 30-40% of NHL, has invasive histologic features and a poor
prognosis if left untreated.
In terms of treatment, for different subtypes of DLBCL, the best regimen for the combination of novel drugs with R-CHOP (rituximab + CHOP) still needs to be explored by more research
.
In addition, immune conjugates and targeted therapies are expected to bring breakthroughs to the treatment of DLBCL, and CAR-T cell therapy and bispecific antibodies may change the pattern
of DLBCL treatment.
For primary central nervous system lymphoma, septepa in combination with conventional chemotherapy may improve efficacy
.
Compared with radiotherapy, ASCT has a similar efficacy, or even better, and better safety profile
.
Professor Franco Cavalli gave a wonderful speech
Erudite and dedicated to discuss the breakthroughs and challenges of immune checkpoint research
Professor Zhang Huilai of Tianjin Medical University Cancer Hospital gave a report
entitled "The New Era of Lymphoma Immunotherapy: Breakthroughs and Challenges in Immune Checkpoint Research" from multiple dimensions such as immune dysregulation mechanism and immunotherapy methods.
Through the interpretation of a series of studies, Professor Zhang Huilai pointed out that the complete response rate of PD-1 monoclonal antibody monotherapy for various lymphoma subtypes is still low, and it is necessary to explore combination treatment options
.
At present, immune checkpoint therapy is advancing to the front line, and new strategies such as combination antibody drug conjugate (ADC) drugs, epigenetic drugs, other targeted therapies and CAR-T are also in
full swing.
For the future application of immune checkpoint research in lymphoma, efforts can be made from
new immune molecular pathways, new mechanisms of tumor immune escape, drug resistance mechanisms, more and more accurate biomarkers, expansion of therapeutic indications, and exploration of combination treatment regimens.
Professor Zhang Huilai gave a wonderful report
Continuing to take stock of the new progress of ADC drug treatment for DLBCL
Professor Xu Wei of the First Affiliated Hospital of Nanjing Medical University elaborated
on the mechanism of action of ADC drugs to efficiently kill tumors, the mechanism of action of the world's first targeting CD79b Polatuzumab vedotin (Pola), and the clinical application of Pola in the treatment of DLBCL.
ADCs overcome some of the limitations
of traditional chemotherapy and targeted therapies by combining the targeted selectivity of monoclonal antibodies with potent cytotoxicity.
Based on leading molecular design and solid clinical exploration, Pola integrates suitable targets, stable point-definite lysis linkers and potent cytotoxic drugs, and has made significant clinical breakthroughs in patients with relapsed refractory and treatment-naïve DLBCL, and the efficacy does not depend on CD79b target expression protein, which is expected to bring new hope for cure to Chinese patients and deserves the attention of
scholars.
Professor Xu Wei gave a wonderful speech
The conference was rich in content and wonderful, and experts at home and abroad enthusiastically shared
the difficult pain points, research progress and future challenges of lymphoma treatment.
On the road of lymphoma diagnosis and treatment development, we still need to work together to bring more benefits to hematological cancer patients, strive for the construction and development of hematology, and contribute wisdom and strength to jointly promote the cause of human health!
Past Recommended 01 Detailed Schedule | 2022 CSCO Academic Annual Conference Harbin Branch &The 7th Anti-leukemia and Lymphoma International Summit Forum invites you to attend (November 10-11) 02 Grand Ceremony Kicks Off and Scores | 2022 CSCO Annual Conference Harbin Branch &The 7th Anti-Leukemia and Lymphoma International Summit Forum was grandly held! 03Sail of IntegrationAcademician Forum Held 04Multi-dimensional Integration of Medical Administration, Medicine, Doctor-Patient to Help the Development of the Blood Field | The conference report session was successfully held05Live up to the times and move forward with dreams | The 2022 CSCO Academic Annual Conference Harbin Branch &The 7th Anti-Leukemia and Lymphoma International Summit Forum ended successfully! 06
Working together, UCLI-CDE Special Session helps innovative drugs reach new peaksThe 7th Anti-leukemia and Lymphoma International Summit Forum
Edited by Hui-Y Reviewed: Irena Typesetting: Wenting Executed by Moly
Disclaimer: This platform is designed to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with
it as soon as possible.
Click to read the original article to see more conference videos
